Source:http://linkedlifedata.com/resource/pubmed/id/11996757
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2002-5-8
|
pubmed:abstractText |
Medical care of patients with essential hypertension implies considerable expenses for the National Health System (NHS). During the performance of clinical trials (CT), the promoter (usually the pharmaceutical industry) covers the expenses of patient care, which implies savings for the NHS. In this work, we quantitated cost savings derived from the participation of patients in clinical trials on essential hypertension in a tertiary care level Insalud hospital.
|
pubmed:language |
spa
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0014-2565
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
202
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
66-72
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading | |
pubmed:year |
2002
|
pubmed:articleTitle |
[Cost savings derived from the participation in clinical trials].
|
pubmed:affiliation |
Servicio de Medicina Interna, Hospital La Paz, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain. jgarciapuig@navegalia.com
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|